VEGFR-2-IN-47 (compound 7g) is a potent VEGFR-2 inhibitor with an IC50 of 0.072 μM. It induces G2/M phase cell cycle arrest and promotes apoptosis in MCF-7 cells, enhancing immune modulation by decreasing TNF-α levels and increasing IL-2 levels. VEGFR-2-IN-47 shows potential for research in breast cancer and liver cancer.

VEGFR2:0.072 μM

VEGFR-2-IN-47 (compound 7g) exhibits highly selective anti-proliferative activity against MCF-7 and HepG2 cancer cells, with IC 50 values of 19.35 and 27.89 μM, respectively, and demonstrates low toxicity towards normal WI-38 cells, with an IC 50 value of 51.14 μM, indicating good safety. At a concentration of 19.35 μM over 72 hours, VEGFR-2-IN-47 causes a reduction in the G0/G1 and S phases and an accumulation in the G2/M phase in MCF-7 cells. Additionally, VEGFR-2-IN-47 enhances apoptosis by downregulating Bcl-2 and upregulating Bax levels, while also modulating the immune response by decreasing TNF-α and increasing IL-2 levels in MCF-7 cells.